期刊文献+

他汀类降脂药在慢性肾病防治中的研究进展 被引量:4

下载PDF
导出
摘要 近年国内外有关资料表明,慢性肾病(CKD)的发病率、患病率均明显上升,世界各国面临的防治形势相当严峻。CKD的病因可涉及肾小球病变、肾小管间质病变、肾血管病变等方面。在美国等发达国家,糖尿病肾病、高血压肾小动脉硬化已成为CKD的主要病因;在我国国内,这两种疾病在CKD各种病因中的发生率仍位居原发性肾小球肾炎之后,但也有明显增高趋势。
出处 《中国中西医结合肾病杂志》 2012年第10期929-931,共3页 Chinese Journal of Integrated Traditional and Western Nephrology
  • 相关文献

参考文献28

  • 1Shepherd J, Kastelein JJ, Bittner V, et al. Treating to New Targets Investigators. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Target (TNT) study. Clin J Am Soc Nephrol, 2007,2(6) :1131 - 1139.
  • 2Faergeman O, Hill L, Windler E, et al. ECLIPSE Study Investiga- tors. Efficacy and tolerability of rosuvastatin and atorvastatin when force- titrated in patients with primary hypercholesterl- emia: results from the ECLIPSE study. Cardiology, 2008, 111 (4) :219 -228.
  • 3Keller D. Atorvastatin beats rosuvastatin in protecting kidneys in diabetic and nondiabetic patients. XLVII European Renal Associ- ation- European Dialysis and Transplant Association (ERA - EDTA) Congress. Presented 2010. Medscape Medical News.
  • 4Toth PP, Dayspring TD. Drug safety evaluation of rosuvastatin. Expert Opin Drug Saf,2011,10(6) :969 -986.
  • 5Keane WF, Tomassini JE, Neff DR. Lipid abnormalities in pa- tients with chronic kidney disease. Contrib Nephrol, 2011,171 (1) :135 -142.
  • 6Ozsoy RC, van der Steeg WA, Kastelein JJ ,et al. Dyslipidaemia as predictor of progressive renal failure and the impact of treat- ment with atorvastatin. Nephrol Dial Transplant, 2007,22 ( 6 ) : 1578 - 1586.
  • 7Zharfbin A. Dyslipidemia in patients being treated with peritonealdialysis. Vnitr Lek, 2006,52 ( 11 ) : 1051 - 1057.
  • 8Kanbay M, Turgut F, Covic A, et al. Statin treatment for dyslipi- demia in chronic kidney disease and renal transplantation:a re- view of the evidence. J Nephroi,2009,22 (5) :598 - 609.
  • 9Nagase M, Shibata S, Yoshida S, et al. Podocyte injury underlies the glomerulopathy of Dahl salt - hypertensive rats and is re- versed by aldosterone blocker. Hypertension ,2006,47 (6) : 1084 - 1093.
  • 10Zhou MS, Hernandez Schulman I, Pagano PJ, et al. Reduced NADPH oxidase in low renin hypertension:link among angioten- sion Ⅱ, atherogenesis, and blood pressure. Hypertension,2006, 47(1) :8t -86.

共引文献63

同被引文献24

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部